SRPT - Sarepta Therapeutics, Inc.
After hours:
| Previous close | 125.16 |
| Open | 125.48 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1000 |
| Day's range | 125.43 - 127.62 |
| 52-week range | 61.28 - 159.89 |
| Volume | |
| Avg. volume | 1,648,443 |
| Market cap | 11.753B |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -12.85 |
| Earnings date | 31 Jul 2023 - 04 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 173.74 |
ZacksWhy Is Sarepta Therapeutics (SRPT) Down 1.5% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Motley FoolIs Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval?
Shares of Sarepta Therapeutics (NASDAQ: SRPT) nosedived last week as the Food and Drug Administration (FDA) did not approve the company's gene therapy treatment, SRP-9001. Should investors be worried about this development, or is this just a bump in the road for the biotech stock? Investors were expecting a decision on Sarepta's gene therapy SRP-9001 this week.
Business WireSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 31, 2023--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 33 individuals hired by Sarepta in May 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Motley FoolWhy Shares of Sarepta Therapeutics Are Dropping Wednesday
Shares of Sarepta Therapeutics (NASDAQ: SRPT), which focuses on genetic treatments for rare diseases, were down 11.5% Wednesday afternoon after the Food and Drug Administration (FDA) pushed back its Prescription Drug User Fee Act (PDUFA) date on a Duchenne muscular dystrophy therapy candidate. The biotech stock is up less than 1% so far this year. The FDA gave Sarepta good news and bad news on Wednesday regarding the company's gene transfer therapy, SRP-9001 (delandistrogene moxeparvovec), designed to treat ambulatory patients with Duchenne muscular dystrophy (DMD) who have a mutation of the DMD gene.
Motley Fool2 Under-the-Radar Biotech Stocks to Buy in 2023
With that said, let's consider two biotech stocks, neither of which is a household name, that could deliver solid returns over the next five years and more: Exelixis (NASDAQ: EXEL) and Sarepta Therapeutics (NASDAQ: SRPT). Oncology is one of the most fiercely competitive therapeutic areas in the biotech industry. Exelixis, a mid-cap biotech, is just a small player in the field.
Business WireSarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
CAMBRIDGE, Mass., May 24, 2023--Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today provided the following update on the Biologics License Application (BLA) for SRP-9001 (delandistrogene moxeparvovec), which is currently under review for the treatment of ambulant individuals with Duchenne muscular dystrophy (DMD) who have a confirmed mutation of the DMD gene.
Motley FoolWhy These 3 Nasdaq Stocks Buckled Today
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.
Motley FoolWhy Sarepta Therapeutics Stock Is Skyrocketing Today
Shares of Sarepta Therapeutics (NASDAQ: SRPT) were skyrocketing 24.9% higher as of 10:37 a.m. ET on Monday. The huge gain came after the company announced Friday evening that a U.S. Food and Drug Administration (FDA) advisory committee voted in support of accelerated approval of SRP-9001 in treating Duchenne muscular dystrophy (DMD). Sarepta said that the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 8-6 in favor of approving SRP-9001.
ReutersSarepta surges after FDA panel backs Duchenne gene therapy
(Reuters) -Shares of Sarepta Therapeutics jumped 25% on Monday as a backing by the U.S. health regulator's advisers increased the certainty of an accelerated approval for the company's gene therapy for a muscle-wasting genetic disorder. Eight of the 14 advisers to the Food and Drug Administration late Friday voted that the company had enough data to support an accelerated approval for its gene therapy for Duchenne muscular dystrophy (DMD). "We are increasingly optimistic that SRP-9001 will be granted accelerated approval, especially as the panel voted in concordance with how we think senior leaders at the agency view the application," said SVB Securities analyst Joseph Schwartz.
Motley Fool2 Supercharged Growth Stocks to Buy Right Now
Despite a possibe economic recession, the ongoing turmoil among regional banks, rumblings of a potential crisis in commercial real estate, stubbornly high inflation, ever-rising interest rates, and a fair amount of geopolitical tumult, growth stocks have been on the upswing in 2023. The tech-heavy Nasdaq Composite, for example, has clocked a remarkable 17.4% gain so far this year. The core reason is that bargain hunters have been snapping up growth stocks of late after their dramatic decline in value in 2022.
Business WireSarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
CAMBRIDGE, Mass., May 12, 2023--Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in support of accelerated approval of SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulatory patients with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene.
Motley FoolWhy Sarepta Therapeutics Stock Faded This Week
Shares of the rare disease juggernaut Sarepta Therapeutics (NASDAQ: SRPT) fell by 12.6% through the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The biotech's stock fell almost on cue ahead of the upcoming advisory committee meeting this Friday for its Duchenne muscular dystrophy (DMD) gene therapy known as SRP-9001. It's almost tradition at this point for smaller companies with high-value product candidates to dip ahead of an advisory committee meeting.
- Investing.com
Weekly biotech pulse: Big catalysts on tap for Sarepta, Roche, Eyenovia, and more
By Vlad Schepkov
Simply Wall St.Institutional investors control 86% of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) and were rewarded last week after stock increased 6.6%
Key Insights Given the large stake in the stock by institutions, Sarepta Therapeutics' stock price might be vulnerable...
ZacksSarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Sarepta (SRPT) delivers narrower-than-expected loss per share in first-quarter 2023. Total revenues beat estimates on the back of strong product sales growth during the quarter.
Motley FoolSarepta Therapeutics (SRPT) Q1 2023 Earnings Call Transcript
At this time, I'll turn the call over to Mary Jenkins, associate director, investor relations. Joining us on the call today are Doug Ingram, Ian Estepan, Dallan Murray, and Dr. After our formal remarks, we'll open the call for Q&A. I'd like to note that during this call, we'll be making a number of forward-looking statements.
ZacksSarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 33.56% and 13.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireSarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass., May 02, 2023--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2023.
ZacksSeres Therapeutics (MCRB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireSarepta Therapeutics to Announce First Quarter 2023 Financial Results
CAMBRIDGE, Mass., April 25, 2023--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2023 financial results after the Nasdaq Global Market closes on Tuesday, May 2, 2023. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2023 financial results.
- Simply Wall St.
Risks To Shareholder Returns Are Elevated At These Prices For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
It's not a stretch to say that Sarepta Therapeutics, Inc.'s ( NASDAQ:SRPT ) price-to-sales (or "P/S") ratio of 11.8x...
ReutersSarepta shares drop as report says FDA almost rejected under-review gene therapy
Shares of Catalent Inc, which holds the contract manufacturing rights for the therapy, fell nearly 5% to $61.22 premarket. Some staff at the FDA had reached a "non-binding conclusion" that Sarepta's gene therapy should not be given approval, prompting FDA official Peter Marks to intervene and schedule an advisory meeting instead, Stat News reported, citing sources.
Business WireSarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
CAMBRIDGE, Mass., April 10, 2023--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the date of the U.S. Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA) is May 12, 2023. The advisory committee meeting will be hosted as a virtual meeting. SRP-9001 is Sarepta’s investigational gene therapy for the
Motley Fool2 Top Growth Stocks That Could Soar This Spring
Exciting news on the way for both of these companies could send their stock prices screaming higher.